

Eiger Bio Strengthens Senior Management Team with Announcement of Debra Odink, PhD as Senior Vice President of Technical Operations

PALO ALTO, Calif., May 3, 2016 / PRNewswire / — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a biopharmaceutical company focused on the development and commercialization of targeted therapies for Orphan diseases, announced today the appointment of Debra Odink, PhD as the Company's Senior Vice President of Technical Operations.

"This year, Eiger plans to dose patients in eight different Phase 2 clinical studies in four diverse orphan therapeutic programs across international sites involving two different small molecules, one peptide and one pegylated biologic. We are very pleased to appoint Dr. Odink at this time to lead Technical Operations," said David Cory, President and CEO of Eiger. "Debra's many years of manufacturing and CMC experience, overseeing multiple programs including small molecules and biologics, at large pharmaceutical and start-up biotechnology companies will significantly strengthen our ability to execute."

Dr. Odink added, "Eiger has built a robust pipeline by matching multiple, diverse orphan programs and novel targets with well characterized clinical stage assets. The company has uniquely positioned itself to quickly and efficiently generate proof of concept clinical data in multiple orphan programs and generate value."

Most recently, Dr. Odink was the Chief Technical Officer and Senior Vice President at Anthera Pharmaceuticals. Previously, she was Vice President of Pharmaceutical Chemistry and Product Development at Peninsula Pharmaceuticals, acquired by Johnson and Johnson in 2005. Dr. Odink began her career in industry at Roche including positions as Principal Research Scientist and CMC Leader.

Dr. Odink received a B.S. in Chemistry from California State University, Stanislaus and a Ph.D. in Chemistry from the University of California, Davis.

About Eiger

Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives, intentions, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, whether or not pegylated interferon lambda-1a or lonafarnib or ubenimex may be further developed and approved, statements relating to the availability of cash for Eiger’s future operations, Eiger’s ability to develop its drug candidates for potential commercialization, the timing of the commencement and number and completion of Phase 2 trials and whether the products can be successfully developed or commercialized. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including the risks described in the “Risk Factors” sections in the Annual Report on Form 10-K for the period ended December 31, 2015 and Eiger’s periodic reports filed with the SEC. Eiger does not assume any obligation to update any forward-looking statements, except as required by law.



SOURCE Eiger Bio, Inc.

Investors: Jim Shaffer, Eiger Bio, Inc., 919-345-4256, jshaffer@eigerbio.com